Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma

(MedPage Today) -- CHICAGO -- Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news